首页 > 最新文献

Pediatric Diabetes最新文献

英文 中文
Maternal Autoimmune Disease and Childhood-Onset Type 1 Diabetes: A Nationwide Population-Based Nested Case-Control Study. 母体自身免疫性疾病和儿童期发病1型糖尿病:一项基于全国人群的巢式病例对照研究
IF 5.6 3区 医学 Q2 ENDOCRINOLOGY & METABOLISM Pub Date : 2026-01-20 eCollection Date: 2026-01-01 DOI: 10.1155/pedi/3418021
Hsin-Chien Yen, Ching-Heng Lin, Ming-Chih Lin

Introduction: Type 1 diabetes mellitus (T1DM) is an autoimmune disease that damages insulin-producing pancreatic cells, often appearing in childhood. Global incidence is rising at 2%-3% yearly. Its exact cause is unclear. Prenatal exposures and maternal autoimmune disorders have been reported as potential risk factors. This study aimed to explore how maternal autoimmune conditions might correlate with the onset of T1DM, employing a population-focused approach.

Methods: This is a retrospective population-based cohort study with a nested case-control analysis. Primary data were derived from the Maternal and Child Health Database (MCHD) and the National Health Insurance Research Database (NHIRD). This study enrolled a total of 2,036,051 newborns born between 2004 and 2014. They were followed up until the end of 2020. A total of 1273 children under the age of 17 with T1DM were identified from 2004 to 2020. A 1:10 control group, matched by birth date and sex, was selected for comparison. T1DM patients were identified through the Catastrophic Illness Registry Database. Maternal autoimmune diseases were determined using the primary diagnosis codes for hospitalizations and outpatients' visits.

Results: After adjusting for cofactors, the offspring of mothers with an autoimmune disease had a higher risk of T1DM (adjusted odds ratio [aOR] 1.95, 95% confidence interval [CI]: 1.45-2.63, p  < 0.001). For individual autoimmune diseases, T1DM (aOR: 6.81, 95% CI: 2.30-20.16, p  < 0.001), Hashimoto thyroiditis (aOR: 3.75, 95% CI: 1.85-7.60, p  < 0.001), rheumatoid arthritis (aOR: 2.49, 95% CI: 1.08-5.77, p = 0.033), and Graves' disease (aOR: 1.85, 95% CI: 1.14-2.99, p = 0.013) significantly increase the risk of developing T1DM in their children.

Conclusions: Offspring of mothers diagnosed with autoimmune disease, notably T1DM, autoimmune thyroiditis, and rheumatoid arthritis, may indeed have a heightened likelihood of developing T1DM. These findings underscore the importance of targeted screening programs for T1DM in children of affected mothers.

1型糖尿病(T1DM)是一种自身免疫性疾病,损害产生胰岛素的胰腺细胞,常出现在儿童时期。全球发病率以每年2%-3%的速度上升。其确切原因尚不清楚。据报道,产前暴露和母体自身免疫性疾病是潜在的危险因素。本研究旨在探讨母体自身免疫性疾病如何与T1DM发病相关,采用以人群为中心的方法。方法:这是一项基于人群的回顾性队列研究,采用嵌套病例对照分析。主要数据来自妇幼健康数据库(MCHD)和国家健康保险研究数据库(NHIRD)。这项研究共招募了2004年至2014年间出生的2,036,051名新生儿。他们被跟踪调查到2020年底。从2004年到2020年,共有1273名17岁以下的T1DM儿童被确诊。以出生日期和性别相匹配的1:10对照组进行比较。通过灾难性疾病登记数据库确定T1DM患者。使用住院和门诊就诊的初级诊断代码确定母体自身免疫性疾病。结果:在校正辅助因素后,患有自身免疫性疾病的母亲的后代患T1DM的风险更高(校正优势比[aOR] 1.95, 95%置信区间[CI]: 1.45-2.63, p < 0.001)。对于个体自身免疫性疾病,T1DM (aOR: 6.81, 95% CI: 2.30-20.16, p < 0.001)、桥本甲状腺炎(aOR: 3.75, 95% CI: 1.85-7.60, p < 0.001)、类风湿关节炎(aOR: 2.49, 95% CI: 1.08-5.77, p = 0.033)和Graves病(aOR: 1.85, 95% CI: 1.14-2.99, p = 0.013)显著增加其子女发生T1DM的风险。结论:被诊断为自身免疫性疾病的母亲的后代,特别是T1DM、自身免疫性甲状腺炎和类风湿性关节炎,确实有更高的可能性发展为T1DM。这些发现强调了对患病母亲的孩子进行有针对性的T1DM筛查的重要性。
{"title":"Maternal Autoimmune Disease and Childhood-Onset Type 1 Diabetes: A Nationwide Population-Based Nested Case-Control Study.","authors":"Hsin-Chien Yen, Ching-Heng Lin, Ming-Chih Lin","doi":"10.1155/pedi/3418021","DOIUrl":"10.1155/pedi/3418021","url":null,"abstract":"<p><strong>Introduction: </strong>Type 1 diabetes mellitus (T1DM) is an autoimmune disease that damages insulin-producing pancreatic cells, often appearing in childhood. Global incidence is rising at 2%-3% yearly. Its exact cause is unclear. Prenatal exposures and maternal autoimmune disorders have been reported as potential risk factors. This study aimed to explore how maternal autoimmune conditions might correlate with the onset of T1DM, employing a population-focused approach.</p><p><strong>Methods: </strong>This is a retrospective population-based cohort study with a nested case-control analysis. Primary data were derived from the Maternal and Child Health Database (MCHD) and the National Health Insurance Research Database (NHIRD). This study enrolled a total of 2,036,051 newborns born between 2004 and 2014. They were followed up until the end of 2020. A total of 1273 children under the age of 17 with T1DM were identified from 2004 to 2020. A 1:10 control group, matched by birth date and sex, was selected for comparison. T1DM patients were identified through the Catastrophic Illness Registry Database. Maternal autoimmune diseases were determined using the primary diagnosis codes for hospitalizations and outpatients' visits.</p><p><strong>Results: </strong>After adjusting for cofactors, the offspring of mothers with an autoimmune disease had a higher risk of T1DM (adjusted odds ratio [aOR] 1.95, 95% confidence interval [CI]: 1.45-2.63, <i>p</i>  < 0.001). For individual autoimmune diseases, T1DM (aOR: 6.81, 95% CI: 2.30-20.16, <i>p</i>  < 0.001), Hashimoto thyroiditis (aOR: 3.75, 95% CI: 1.85-7.60, <i>p</i>  < 0.001), rheumatoid arthritis (aOR: 2.49, 95% CI: 1.08-5.77, <i>p</i> = 0.033), and Graves' disease (aOR: 1.85, 95% CI: 1.14-2.99, <i>p</i> = 0.013) significantly increase the risk of developing T1DM in their children.</p><p><strong>Conclusions: </strong>Offspring of mothers diagnosed with autoimmune disease, notably T1DM, autoimmune thyroiditis, and rheumatoid arthritis, may indeed have a heightened likelihood of developing T1DM. These findings underscore the importance of targeted screening programs for T1DM in children of affected mothers.</p>","PeriodicalId":19797,"journal":{"name":"Pediatric Diabetes","volume":"2026 ","pages":"3418021"},"PeriodicalIF":5.6,"publicationDate":"2026-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12820419/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146030607","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
From Pathophysiology to Treatment: Contemporary Approaches to CFRD in the Pediatric and Adolescent Population. 从病理生理学到治疗:儿科和青少年CFRD的当代治疗方法。
IF 5.6 3区 医学 Q2 ENDOCRINOLOGY & METABOLISM Pub Date : 2026-01-16 eCollection Date: 2026-01-01 DOI: 10.1155/pedi/5539725
Dogus Vuralli
<p><p>Cystic fibrosis-related diabetes (CFRD) is the most prevalent nonrespiratory complication of cystic fibrosis (CF), with its prominence growing as survival rates improve due to advances in CFTR modulator therapies. Its prevalence increases with age, affecting nearly 50% of patients with CF (PwCF) over 30 years old. CFRD primarily results from progressive pancreatic fibrosis leading to insulin deficiency, further compounded by intermittent insulin resistance during pulmonary exacerbations and systemic inflammation. Key risk factors include pancreatic insufficiency, female sex, severe <i>CFTR</i> genotypes (such as p.F508del homozygosity), CF-related liver disease, and family history of type 2 diabetes. The early stages of CFRD are often asymptomatic, necessitating proactive screening. Annual oral glucose tolerance tests (OGTT) beginning at age 10 are challenging to perform but remain the gold standard for early detection, while continuous glucose monitoring (CGM) is increasingly recognized as a valuable complementary tool. Diagnosis is based on standard OGTT criteria, with indeterminate glycemia (INDET) and impaired glucose tolerance (IGT) recognized as prediabetic stages requiring close monitoring. Even early abnormalities in glucose metabolism may be associated with declines in pulmonary function and nutritional status, underscoring the need for rigorous surveillance and timely therapeutic intervention. Early initiation of insulin treatment can substantially mitigate these complications and improve clinical outcomes. Insulin remains the cornerstone of CFRD management, is recommended as the primary treatment for patients with CFRD (PwCFRD) rather than dietary modification alone. While pilot studies and observational cohorts have suggested potential benefits of early insulin treatment in individuals with early glycemic abnormalities such as INDET or IGT, findings from randomized controlled trials do not provide evidence to justify initiating insulin before CFRD is established. Management strategies should be individualized, with personalized glycemic targets. Insulin dosing aims to achieve the maximum tolerable dose to maintain a low HbA1c, control postprandial hyperglycemia without inducing hypoglycemia, minimize catabolism, and preserve optimal nutrition and pulmonary health without restricting carbohydrate intake. Regular glucose monitoring, quarterly HbA1c measurements, and annual screening for microvascular complications starting 5 years after diagnosis are essential to optimize outcomes. The advent of CFTR modulator therapies has revolutionized CF care, significantly improving outcomes and quality of life for PwCF. These therapies also show promise in improving glucose regulation and may impact the prevalence, onset, and course of CFRD. However, current data remain inconclusive, and the long-term effects are still being elucidated. Future directions in CFRD research include refining screening protocols, exploring adjunctive noninsulin t
囊性纤维化相关性糖尿病(CFRD)是囊性纤维化(CF)最常见的非呼吸系统并发症,随着CFTR调节剂治疗的进展,生存率提高,其重要性日益增加。其患病率随年龄增长而增加,近50%的CF (PwCF)患者年龄超过30岁。CFRD主要由进行性胰腺纤维化导致胰岛素缺乏引起,在肺部恶化和全身性炎症期间,间歇性胰岛素抵抗进一步加剧。关键危险因素包括胰腺功能不全、女性、严重的CFTR基因型(如p.F508del纯合子)、cf相关肝病和2型糖尿病家族史。CFRD的早期阶段通常是无症状的,需要进行主动筛查。从10岁开始进行年度口服葡萄糖耐量试验(OGTT)具有挑战性,但仍然是早期检测的金标准,而连续葡萄糖监测(CGM)越来越被认为是一种有价值的补充工具。诊断基于OGTT标准,不确定血糖(INDET)和糖耐量受损(IGT)被认为是糖尿病前期,需要密切监测。甚至早期的糖代谢异常也可能与肺功能和营养状况的下降有关,这强调了严格监测和及时治疗干预的必要性。早期开始胰岛素治疗可以大大减轻这些并发症和改善临床结果。胰岛素仍然是CFRD治疗的基石,被推荐作为CFRD (PwCFRD)患者的主要治疗方法,而不是单纯的饮食调整。虽然试点研究和观察性队列提示早期胰岛素治疗对早期血糖异常(如INDET或IGT)患者有潜在益处,但随机对照试验的结果并没有提供证据证明在CFRD确定之前开始胰岛素治疗是合理的。治疗策略应个体化,有个体化的血糖目标。胰岛素给药的目的是达到最大耐受剂量,以维持较低的HbA1c,控制餐后高血糖而不引起低血糖,减少分解代谢,在不限制碳水化合物摄入的情况下保持最佳营养和肺部健康。定期血糖监测,每季度HbA1c测量,并在诊断后5年开始每年筛查微血管并发症是优化结果的必要条件。CFTR调节疗法的出现彻底改变了CF治疗,显著改善了PwCF的预后和生活质量。这些疗法也显示出改善血糖调节的希望,并可能影响CFRD的患病率、发病和病程。然而,目前的数据仍不确定,长期影响仍有待阐明。CFRD研究的未来方向包括改进筛选方案,探索辅助非胰岛素治疗,以及开发预测性生物标志物。本文综述了目前对CFRD病理生理、诊断和治疗策略的认识,强调了在CF治疗方法不断发展的背景下,早期干预和个性化护理的重要性,以及它们改善PwCF预后的潜力。
{"title":"From Pathophysiology to Treatment: Contemporary Approaches to CFRD in the Pediatric and Adolescent Population.","authors":"Dogus Vuralli","doi":"10.1155/pedi/5539725","DOIUrl":"10.1155/pedi/5539725","url":null,"abstract":"&lt;p&gt;&lt;p&gt;Cystic fibrosis-related diabetes (CFRD) is the most prevalent nonrespiratory complication of cystic fibrosis (CF), with its prominence growing as survival rates improve due to advances in CFTR modulator therapies. Its prevalence increases with age, affecting nearly 50% of patients with CF (PwCF) over 30 years old. CFRD primarily results from progressive pancreatic fibrosis leading to insulin deficiency, further compounded by intermittent insulin resistance during pulmonary exacerbations and systemic inflammation. Key risk factors include pancreatic insufficiency, female sex, severe &lt;i&gt;CFTR&lt;/i&gt; genotypes (such as p.F508del homozygosity), CF-related liver disease, and family history of type 2 diabetes. The early stages of CFRD are often asymptomatic, necessitating proactive screening. Annual oral glucose tolerance tests (OGTT) beginning at age 10 are challenging to perform but remain the gold standard for early detection, while continuous glucose monitoring (CGM) is increasingly recognized as a valuable complementary tool. Diagnosis is based on standard OGTT criteria, with indeterminate glycemia (INDET) and impaired glucose tolerance (IGT) recognized as prediabetic stages requiring close monitoring. Even early abnormalities in glucose metabolism may be associated with declines in pulmonary function and nutritional status, underscoring the need for rigorous surveillance and timely therapeutic intervention. Early initiation of insulin treatment can substantially mitigate these complications and improve clinical outcomes. Insulin remains the cornerstone of CFRD management, is recommended as the primary treatment for patients with CFRD (PwCFRD) rather than dietary modification alone. While pilot studies and observational cohorts have suggested potential benefits of early insulin treatment in individuals with early glycemic abnormalities such as INDET or IGT, findings from randomized controlled trials do not provide evidence to justify initiating insulin before CFRD is established. Management strategies should be individualized, with personalized glycemic targets. Insulin dosing aims to achieve the maximum tolerable dose to maintain a low HbA1c, control postprandial hyperglycemia without inducing hypoglycemia, minimize catabolism, and preserve optimal nutrition and pulmonary health without restricting carbohydrate intake. Regular glucose monitoring, quarterly HbA1c measurements, and annual screening for microvascular complications starting 5 years after diagnosis are essential to optimize outcomes. The advent of CFTR modulator therapies has revolutionized CF care, significantly improving outcomes and quality of life for PwCF. These therapies also show promise in improving glucose regulation and may impact the prevalence, onset, and course of CFRD. However, current data remain inconclusive, and the long-term effects are still being elucidated. Future directions in CFRD research include refining screening protocols, exploring adjunctive noninsulin t","PeriodicalId":19797,"journal":{"name":"Pediatric Diabetes","volume":"2026 ","pages":"5539725"},"PeriodicalIF":5.6,"publicationDate":"2026-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12811412/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145998680","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Use of Dapagliflozin in the Treatment of Children With Severe Insulin Resistance. 达格列净治疗儿童严重胰岛素抵抗的疗效观察。
IF 5.6 3区 医学 Q2 ENDOCRINOLOGY & METABOLISM Pub Date : 2025-12-20 eCollection Date: 2025-01-01 DOI: 10.1155/pedi/6859764
Najyya Attia, Khalid Al Noaim, Manal Mustafa, Suliman H Al Fifi, Ibrahim Al Alwan, Nandu Thalange, Amir Babiker

Background: Managing severe insulin resistance (IR) is challenging, necessitating a multifaceted approach, including dietary restriction, exercise, and pharmacotherapy. This paper will detail our utilization of dapagliflozin in a series of cases involving patients with severe IR of various etiology and inadequate glycemic control.

Case studies: We describe six cases of extreme IR with distinct clinical diagnoses: four with Rabson-Mendenhall syndrome (RMS), one with IR type 1A, and a patient with type 1 diabetes mellitus (T1DM) and severe subcutaneous (SC) IR. These cases exhibit the observable characteristics of IR, characterized by an inability to effectively manage blood glucose (BG) with a standard treatment plan. Every case had a remarkable response to dapagliflozin. Subsequent assessment demonstrated improved HgbA1C, fasting glucose, insulin, and C-peptide concentrations. Furthermore, several cases demonstrated improvement in the clinical manifestations of IR following the administration of dapagliflozin, while others showed a reduction in the frequency of diabetic ketoacidosis (DKA). There were no documented adverse reactions with the use of dapagliflozin for a duration of 2-4 years in these patients.

Conclusion: Dapagliflozin appeared both safe and effective as a standalone treatment or when used alongside other antidiabetes medications such as insulin in a case series of children with T1DM and severe IR or IR syndromes (IRS).

背景:管理严重胰岛素抵抗(IR)是具有挑战性的,需要多方面的方法,包括饮食限制,运动和药物治疗。本文将详细介绍我们在一系列涉及各种病因和血糖控制不足的严重IR患者的病例中使用达格列净的情况。病例研究:我们描述了6例具有不同临床诊断的极端IR: 4例患有Rabson-Mendenhall综合征(RMS), 1例患有IR 1A型,1例患有1型糖尿病(T1DM)和严重皮下IR (SC)。这些病例表现出可观察到的IR特征,其特征是无法用标准治疗方案有效控制血糖(BG)。每个病例对达格列净都有显著的反应。随后的评估显示改善了糖化血红蛋白、空腹血糖、胰岛素和c肽浓度。此外,一些病例在服用达格列净后IR的临床表现得到改善,而另一些病例则显示糖尿病酮症酸中毒(DKA)的发生率降低。在这些患者中,使用达格列净2-4年没有记录的不良反应。结论:对于患有T1DM和严重IR或IR综合征(IRS)的儿童,达格列净作为单独治疗或与其他抗糖尿病药物(如胰岛素)一起使用,既安全又有效。
{"title":"The Use of Dapagliflozin in the Treatment of Children With Severe Insulin Resistance.","authors":"Najyya Attia, Khalid Al Noaim, Manal Mustafa, Suliman H Al Fifi, Ibrahim Al Alwan, Nandu Thalange, Amir Babiker","doi":"10.1155/pedi/6859764","DOIUrl":"10.1155/pedi/6859764","url":null,"abstract":"<p><strong>Background: </strong>Managing severe insulin resistance (IR) is challenging, necessitating a multifaceted approach, including dietary restriction, exercise, and pharmacotherapy. This paper will detail our utilization of dapagliflozin in a series of cases involving patients with severe IR of various etiology and inadequate glycemic control.</p><p><strong>Case studies: </strong>We describe six cases of extreme IR with distinct clinical diagnoses: four with Rabson-Mendenhall syndrome (RMS), one with IR type 1A, and a patient with type 1 diabetes mellitus (T1DM) and severe subcutaneous (SC) IR. These cases exhibit the observable characteristics of IR, characterized by an inability to effectively manage blood glucose (BG) with a standard treatment plan. Every case had a remarkable response to dapagliflozin. Subsequent assessment demonstrated improved HgbA1C, fasting glucose, insulin, and C-peptide concentrations. Furthermore, several cases demonstrated improvement in the clinical manifestations of IR following the administration of dapagliflozin, while others showed a reduction in the frequency of diabetic ketoacidosis (DKA). There were no documented adverse reactions with the use of dapagliflozin for a duration of 2-4 years in these patients.</p><p><strong>Conclusion: </strong>Dapagliflozin appeared both safe and effective as a standalone treatment or when used alongside other antidiabetes medications such as insulin in a case series of children with T1DM and severe IR or IR syndromes (IRS).</p>","PeriodicalId":19797,"journal":{"name":"Pediatric Diabetes","volume":"2025 ","pages":"6859764"},"PeriodicalIF":5.6,"publicationDate":"2025-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12717530/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145804914","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Examining the Cognitive, Practical, and Emotional Demands of Managing Physical Activity in Adolescents With Type 1 Diabetes: A Qualitative Study With Adolescents, Parents, and Healthcare Professionals. 检查1型糖尿病青少年管理身体活动的认知、实践和情感需求:一项青少年、父母和医疗保健专业人员的定性研究
IF 5.6 3区 医学 Q2 ENDOCRINOLOGY & METABOLISM Pub Date : 2025-12-19 eCollection Date: 2025-01-01 DOI: 10.1155/pedi/4578096
Emma Joanne Cockcroft, Jane Rebecca Smith, Jenny Lloyd, Louie Johnson, Richard Pulsford, Ross Clarke, Parth Narendran, Gina Gardener, Tallulah Ngamy, Renuka Priyani Dias, Robert Charles Andrews

Objective: Adolescents with type 1 diabetes (T1D) face unique barriers to physical activity (PA), and most do not meet recommended targets despite its recognised health benefits. To address the lack of tailored, evidence-based support for this group, this study explores how adolescents manage PA and how it is influenced by the wider support system, including parents, carers, and healthcare professionals (HCPs).

Research design and methods: Semi-structured interviews were conducted with adolescents with T1D (n = 11), parents/carers (n = 15), and HCPs (n = 11). Adolescents were aged between 12 and 18 (64% female). HCPs were dieticians (n = 7), nurses (n = 2), a doctor (n = 1) and a health and wellbeing practitioner (n = 1). Interviews explored practical, emotional, and contextual factors influencing PA. Data were analysed using thematic analysis.

Results: Participants described cognitive, emotional, and practical demands of managing T1D during PA. Thematic analysis identified three overarching themes: (1) the mental effort required to manage diabetes with PA, including parental anxiety, desire for normality, and unpredictability of glucose responses; (2) practical and organisational challenges, such as access to supportive environments, technology, and activity-specific logistics; and (3) adaptive management strategies, including trial and error, parental involvement, peer learning, and variable clinical support. Current support was often generic, leading families to rely on self-devised strategies and informal networks to support their individual needs.

Conclusion: Enhanced, youth-friendly, and activity-specific guidance is needed for adolescents with T1D. This should include training for healthcare professionals, teachers, and coaches. Future work should prioritise the co-design of resources and interventions with young people and families, integrating structured peer support.

目的:患有1型糖尿病(T1D)的青少年在身体活动(PA)方面面临独特的障碍,尽管其公认的健康益处,但大多数人没有达到推荐的目标。为了解决这一群体缺乏量身定制的、基于证据的支持的问题,本研究探讨了青少年如何管理PA,以及它如何受到更广泛的支持系统的影响,包括父母、照顾者和医疗保健专业人员(HCPs)。研究设计和方法:对患有T1D的青少年(n = 11)、父母/照顾者(n = 15)和医护人员(n = 11)进行半结构化访谈。青少年年龄在12至18岁之间(64%为女性)。HCPs包括营养师(n = 7)、护士(n = 2)、医生(n = 1)和健康保健从业者(n = 1)。访谈探讨了影响PA的实际、情感和情境因素。采用专题分析对数据进行分析。结果:参与者描述了在PA期间管理T1D的认知、情感和实际需求。主题分析确定了三个主要主题:(1)管理PA患者糖尿病所需的精神努力,包括父母的焦虑、对正常的渴望和葡萄糖反应的不可预测性;(2)实际和组织上的挑战,如获得支持性环境、技术和特定活动的后勤;(3)适应性管理策略,包括试错法、父母参与、同伴学习和可变临床支持。目前的支助往往是一般性的,导致家庭依靠自己制定的战略和非正式网络来支持其个人需要。结论:需要加强对青少年T1D患者的青少年友好型和活动特异性指导。这应包括对医疗保健专业人员、教师和教练的培训。未来的工作应优先考虑与年轻人和家庭共同设计资源和干预措施,并整合有组织的同伴支持。
{"title":"Examining the Cognitive, Practical, and Emotional Demands of Managing Physical Activity in Adolescents With Type 1 Diabetes: A Qualitative Study With Adolescents, Parents, and Healthcare Professionals.","authors":"Emma Joanne Cockcroft, Jane Rebecca Smith, Jenny Lloyd, Louie Johnson, Richard Pulsford, Ross Clarke, Parth Narendran, Gina Gardener, Tallulah Ngamy, Renuka Priyani Dias, Robert Charles Andrews","doi":"10.1155/pedi/4578096","DOIUrl":"10.1155/pedi/4578096","url":null,"abstract":"<p><strong>Objective: </strong>Adolescents with type 1 diabetes (T1D) face unique barriers to physical activity (PA), and most do not meet recommended targets despite its recognised health benefits. To address the lack of tailored, evidence-based support for this group, this study explores how adolescents manage PA and how it is influenced by the wider support system, including parents, carers, and healthcare professionals (HCPs).</p><p><strong>Research design and methods: </strong>Semi-structured interviews were conducted with adolescents with T1D (<i>n</i> = 11), parents/carers (<i>n</i> = 15), and HCPs (<i>n</i> = 11). Adolescents were aged between 12 and 18 (64% female). HCPs were dieticians (<i>n</i> = 7), nurses (<i>n</i> = 2), a doctor (<i>n</i> = 1) and a health and wellbeing practitioner (<i>n</i> = 1). Interviews explored practical, emotional, and contextual factors influencing PA. Data were analysed using thematic analysis.</p><p><strong>Results: </strong>Participants described cognitive, emotional, and practical demands of managing T1D during PA. Thematic analysis identified three overarching themes: (1) the mental effort required to manage diabetes with PA, including parental anxiety, desire for normality, and unpredictability of glucose responses; (2) practical and organisational challenges, such as access to supportive environments, technology, and activity-specific logistics; and (3) adaptive management strategies, including trial and error, parental involvement, peer learning, and variable clinical support. Current support was often generic, leading families to rely on self-devised strategies and informal networks to support their individual needs.</p><p><strong>Conclusion: </strong>Enhanced, youth-friendly, and activity-specific guidance is needed for adolescents with T1D. This should include training for healthcare professionals, teachers, and coaches. Future work should prioritise the co-design of resources and interventions with young people and families, integrating structured peer support.</p>","PeriodicalId":19797,"journal":{"name":"Pediatric Diabetes","volume":"2025 ","pages":"4578096"},"PeriodicalIF":5.6,"publicationDate":"2025-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12717440/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145804830","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Effect of COVID-19 on Incident Diabetes in Pediatric Patients: Findings From the National COVID-19 Cohort Collaborative (N3C). COVID-19对儿科患者发生糖尿病的影响:来自国家COVID-19队列协作(N3C)的研究结果
IF 5.6 3区 医学 Q2 ENDOCRINOLOGY & METABOLISM Pub Date : 2025-12-05 eCollection Date: 2025-01-01 DOI: 10.1155/pedi/3545727
Rachel Wong, Talia Wiggen, Margaret A Hall, Steven G Johnson, Jared D Huling, Lindsey E Turner, Kenneth J Wilkins, Hsin-Chieh Yeh, Til Stürmer, Carolyn T Bramante, Zachary Butzin-Dozier, John B Buse, Jane Reusch

Objective: Studies showing increased diabetes incidence in pediatric patients after COVID-19 are from data early in the pandemic, and some studies found conflicting results. Our objective was to evaluate trends in pediatric diabetes incidence and whether COVID-19 was associated with increased risk across viral variant periods.

Research design and methods: We conducted a retrospective cohort study using National COVID-19 Cohort Collaborative data to evaluate incident diabetes risk among COVID-19-positive pediatric patients compared to COVID-19-negative patients or controls with acute respiratory illness. Cohorts were weighted on demographics, data site, and body mass index percentile. The primary outcome was the cumulative incidence ratio (CIR) of incident diabetes for each viral variant era.

Results: There was no difference in the risk of incident diabetes in pediatric patients after COVID-19 compared to patients in COVID-19 negative or ARI control groups during any of the viral variant periods (e.g., ancestral period CIR 1.03, 95% CI 0.65-1.41). The predominant subtype of incident diabetes was T2D. Incidence rates over time followed a U-shaped curve, with the highest incidence in the ancestral variant period.

Conclusions: COVID-19 was not associated with an increased risk of diabetes in pediatric patients. Incidence rates were highest early in the pandemic, and mirrored patterns of pandemic-era healthcare utilization. The predominance of incident T2D subtype is concerning for the adverse effects of pandemic-related lifestyle changes among pediatric patients.

目的:显示COVID-19后儿科患者糖尿病发病率增加的研究来自大流行早期的数据,一些研究发现了相互矛盾的结果。我们的目的是评估儿童糖尿病发病率的趋势,以及COVID-19是否与病毒变异期风险增加相关。研究设计和方法:我们采用国家COVID-19队列协作数据进行回顾性队列研究,以评估COVID-19阳性儿科患者与COVID-19阴性患者或急性呼吸道疾病对照组相比发生糖尿病的风险。按人口统计学、数据地点和体重指数百分位数对队列进行加权。主要结局是每个病毒变异时期糖尿病的累积发病率(CIR)。结果:在任何病毒变异期(例如,祖先期CIR 1.03, 95% CI 0.65-1.41), COVID-19后儿科患者与COVID-19阴性或ARI对照组患者发生糖尿病的风险均无差异。糖尿病的主要亚型为T2D。随着时间的推移,发病率呈u型曲线,在祖先变异时期发病率最高。结论:COVID-19与儿科患者糖尿病风险增加无关。发病率在大流行早期最高,反映了大流行时期医疗保健利用的模式。T2D亚型发生率的优势与儿科患者中与大流行相关的生活方式改变的不良影响有关。
{"title":"The Effect of COVID-19 on Incident Diabetes in Pediatric Patients: Findings From the National COVID-19 Cohort Collaborative (N3C).","authors":"Rachel Wong, Talia Wiggen, Margaret A Hall, Steven G Johnson, Jared D Huling, Lindsey E Turner, Kenneth J Wilkins, Hsin-Chieh Yeh, Til Stürmer, Carolyn T Bramante, Zachary Butzin-Dozier, John B Buse, Jane Reusch","doi":"10.1155/pedi/3545727","DOIUrl":"10.1155/pedi/3545727","url":null,"abstract":"<p><strong>Objective: </strong>Studies showing increased diabetes incidence in pediatric patients after COVID-19 are from data early in the pandemic, and some studies found conflicting results. Our objective was to evaluate trends in pediatric diabetes incidence and whether COVID-19 was associated with increased risk across viral variant periods.</p><p><strong>Research design and methods: </strong>We conducted a retrospective cohort study using National COVID-19 Cohort Collaborative data to evaluate incident diabetes risk among COVID-19-positive pediatric patients compared to COVID-19-negative patients or controls with acute respiratory illness. Cohorts were weighted on demographics, data site, and body mass index percentile. The primary outcome was the cumulative incidence ratio (CIR) of incident diabetes for each viral variant era.</p><p><strong>Results: </strong>There was no difference in the risk of incident diabetes in pediatric patients after COVID-19 compared to patients in COVID-19 negative or ARI control groups during any of the viral variant periods (e.g., ancestral period CIR 1.03, 95% CI 0.65-1.41). The predominant subtype of incident diabetes was T2D. Incidence rates over time followed a U-shaped curve, with the highest incidence in the ancestral variant period.</p><p><strong>Conclusions: </strong>COVID-19 was not associated with an increased risk of diabetes in pediatric patients. Incidence rates were highest early in the pandemic, and mirrored patterns of pandemic-era healthcare utilization. The predominance of incident T2D subtype is concerning for the adverse effects of pandemic-related lifestyle changes among pediatric patients.</p>","PeriodicalId":19797,"journal":{"name":"Pediatric Diabetes","volume":"2025 ","pages":"3545727"},"PeriodicalIF":5.6,"publicationDate":"2025-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12707300/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145775186","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Exploring the Influence of a Diabetes Specialty Outpatient Clinic on Adolescents With Type 1 Diabetes in Barbados: A Qualitative Study. 探索糖尿病专科门诊对巴巴多斯1型糖尿病青少年的影响:一项定性研究。
IF 5.6 3区 医学 Q2 ENDOCRINOLOGY & METABOLISM Pub Date : 2025-12-03 eCollection Date: 2025-01-01 DOI: 10.1155/pedi/5454172
Gemma-Ann Benskin, Paula Michele Lashley

Objectives: This study explored the perceptions of adolescents with type 1 diabetes mellitus (T1DM) regarding their self-management and the impact of a diabetes specialty outpatient clinic on their quality of life (QOL) in Barbados.

Design: A qualitative, descriptive-interpretive study using semi-structured online interviews.

Setting: Paediatric diabetes specialty outpatient clinic at the Queen Elizabeth Hospital (QEH), Barbados.

Participants: Twelve adolescents aged 13-17 years with T1DM for > 1 year who attended the diabetes specialty outpatient clinic for at least 6 months.

Methods: Interviews were transcribed verbatim, coded using ATLAS.ti 23, and analysed thematically using a constant comparison approach.

Results: Three organising themes-autonomy, internal resilience and clinic and social support-contributed to the global theme of diabetic health literacy. Participants demonstrated varied levels of diabetes self-management confidence. Clinic interactions, family support and peer understanding were key influences on autonomy and resilience. Adolescents identified a need for age-appropriate communication and psychosocial support.

Conclusions: Diabetic health literacy among Barbadian adolescents is influenced by clinical support, psychosocial resources, and educational strategies. Adolescents' autonomy should be fostered through youth-centred approaches that enhance self-efficacy and support transition readiness.

目的:本研究探讨了巴巴多斯1型糖尿病(T1DM)青少年对自我管理的看法,以及糖尿病专科门诊对他们生活质量(QOL)的影响。设计:采用半结构化在线访谈进行定性、描述性-解释性研究。地点:巴巴多斯伊丽莎白女王医院(QEH)儿科糖尿病专科门诊。参与者:12名13-17岁的青少年,患有T1DM,并在糖尿病专科门诊就诊至少6个月。方法:逐字记录访谈内容,用ATLAS进行编码。Ti 23,并使用恒定比较方法进行主题分析。结果:三个组织主题-自主,内部弹性和临床和社会支持-有助于糖尿病健康素养的全球主题。参与者表现出不同程度的糖尿病自我管理信心。临床互动、家庭支持和同伴理解是影响自主性和弹性的关键因素。青少年认为需要与年龄相适应的交流和社会心理支持。结论:巴巴多斯青少年的糖尿病健康素养受到临床支持、社会心理资源和教育策略的影响。应通过以青年为中心的方法促进青少年的自主性,提高自我效能并支持过渡准备。
{"title":"Exploring the Influence of a Diabetes Specialty Outpatient Clinic on Adolescents With Type 1 Diabetes in Barbados: A Qualitative Study.","authors":"Gemma-Ann Benskin, Paula Michele Lashley","doi":"10.1155/pedi/5454172","DOIUrl":"10.1155/pedi/5454172","url":null,"abstract":"<p><strong>Objectives: </strong>This study explored the perceptions of adolescents with type 1 diabetes mellitus (T1DM) regarding their self-management and the impact of a diabetes specialty outpatient clinic on their quality of life (QOL) in Barbados.</p><p><strong>Design: </strong>A qualitative, descriptive-interpretive study using semi-structured online interviews.</p><p><strong>Setting: </strong>Paediatric diabetes specialty outpatient clinic at the Queen Elizabeth Hospital (QEH), Barbados.</p><p><strong>Participants: </strong>Twelve adolescents aged 13-17 years with T1DM for > 1 year who attended the diabetes specialty outpatient clinic for at least 6 months.</p><p><strong>Methods: </strong>Interviews were transcribed verbatim, coded using ATLAS.ti 23, and analysed thematically using a constant comparison approach.</p><p><strong>Results: </strong>Three organising themes-autonomy, internal resilience and clinic and social support-contributed to the global theme of diabetic health literacy. Participants demonstrated varied levels of diabetes self-management confidence. Clinic interactions, family support and peer understanding were key influences on autonomy and resilience. Adolescents identified a need for age-appropriate communication and psychosocial support.</p><p><strong>Conclusions: </strong>Diabetic health literacy among Barbadian adolescents is influenced by clinical support, psychosocial resources, and educational strategies. Adolescents' autonomy should be fostered through youth-centred approaches that enhance self-efficacy and support transition readiness.</p>","PeriodicalId":19797,"journal":{"name":"Pediatric Diabetes","volume":"2025 ","pages":"5454172"},"PeriodicalIF":5.6,"publicationDate":"2025-12-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12695417/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145743733","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Revealing Monogenic Diabetes: Clinical and Genetic Features of Pediatric MODY Cases in Türkiye: Single Center Experience. 揭示单基因糖尿病:儿童MODY病例的临床和遗传特征:rkiye:单中心经验。
IF 5.6 3区 医学 Q2 ENDOCRINOLOGY & METABOLISM Pub Date : 2025-12-01 eCollection Date: 2025-01-01 DOI: 10.1155/pedi/4035026
Aslihan Sanri, Tugba Kontbay Cetin, Emel Gul Acikgoz, Mehmet Burak Mutlu, Ozlem Sezer
<p><strong>Objective: </strong>Maturity-onset diabetes of the young (MODY) represents a genetically and clinically heterogeneous form of monogenic diabetes caused by defects in pancreatic β-cell function. Accurate molecular diagnosis is essential for distinguishing MODY from type 1 and type 2 diabetes, enabling precision-based management and targeted therapy. This study aimed to evaluate the genetic and clinical features of pediatric patients with MODY, to assess the prevalence of common and rare subtypes, and to report novel pathogenic variants identified in a Turkish cohort.</p><p><strong>Methods: </strong>This single-center, retrospective cohort study evaluated 81 pediatric patients with suspected MODY followed between 2022 and 2025. Genetic analysis was performed using targeted next-generation sequencing (NGS) panels, including <i>HNF4A</i>, <i>GCK</i>, <i>HNF1A</i>, <i>PDX1</i>, <i>HNF1B</i>, <i>NEUROD1</i>, <i>INS</i>, <i>ABCC8</i>, <i>KCNJ11</i>, <i>APPL1</i>, and <i>CEL</i>. Patients were selected based on the presence of at least two clinical features suggestive of MODY, as defined by the 2022 International Society for Pediatric and Adolescent Diabetes (ISPAD) Clinical Practice Consensus Guidelines. Demographic, biochemical, and clinical data were extracted from hospital records and analyzed descriptively.</p><p><strong>Results: </strong>Genetic variants were identified in 25 of 81 patients (30.9%), including pathogenic, likely pathogenic, and variants of uncertain significance (VUS). Of these, 22 variants were classified as pathogenic or likely pathogenic, corresponding to a diagnostic yield of 27.2%. The most frequently affected gene was <i>GCK</i> (72.0%), followed by <i>HNF1A</i> (8.0%), with single cases identified in <i>HNF1B</i>, <i>INS</i>, <i>PDX1</i>, <i>CEL</i>, <i>and KCNJ11</i>. Rare MODY subtypes collectively accounted for 20.0%. Three novel <i>GCK</i> variants c.1055T >C, c.1229A >C, and c.185_186insA were identified. One patient with syndromic features harbored a heterozygous 17q12 microdeletion encompassing <i>HNF1B</i>, approximately 1.5 Mb in size, and presented with global developmental delay, intellectual disability, epilepsy, dysmorphic facial features, persistent hypomagnesemia, and a bicornuate uterus with normal renal structure. Following genetic analysis, two patients had therapy adjustments based on the identified variants.</p><p><strong>Conclusion: </strong>This study underscores the clinical and genetic heterogeneity of MODY in the pediatric population and reinforces the value of comprehensive NGS panels for accurate diagnosis, even in patients who do not fully meet classical MODY criteria. The identification of novel <i>GCK</i> variants and the detection of rare subtypes further expand the mutational and phenotypic spectrum of pediatric monogenic diabetes. These findings highlight the importance of incorporating population-specific genomic data into clinical practice and of periodically re-evaluating gene-di
目的:成熟型糖尿病(MODY)是由胰腺β细胞功能缺陷引起的单基因糖尿病的一种遗传和临床异质性形式。准确的分子诊断对于区分MODY与1型和2型糖尿病至关重要,从而实现基于精确的管理和靶向治疗。本研究旨在评估MODY儿童患者的遗传和临床特征,评估常见和罕见亚型的患病率,并报告在土耳其队列中发现的新的致病变异。方法:这项单中心、回顾性队列研究评估了81例疑似MODY的儿科患者,随访时间为2022年至2025年。采用靶向下一代测序(NGS)面板进行遗传分析,包括HNF4A、GCK、HNF1A、PDX1、HNF1B、NEUROD1、INS、ABCC8、KCNJ11、APPL1和CEL。根据2022年国际儿科和青少年糖尿病学会(ISPAD)临床实践共识指南的定义,根据至少两个提示MODY的临床特征选择患者。从医院记录中提取人口统计学、生化学和临床数据并进行描述性分析。结果:81例患者中有25例(30.9%)发现遗传变异,包括致病性、可能致病性和不确定意义变异(VUS)。其中,22个变异被归类为致病性或可能致病性,相应的诊断率为27.2%。最常见的受影响基因是GCK(72.0%),其次是HNF1A(8.0%),在HNF1B、INS、PDX1、CEL和KCNJ11中发现单个病例。罕见MODY亚型合计占20.0%。鉴定出3个新的GCK变异体C . 1055t >C、C . 1229a >C和C . 185_186insa。1例患者具有综合征特征,其中包含HNF1B的杂合17q12微缺失,大小约为1.5 Mb,表现为整体发育迟缓、智力残疾、癫痫、面部畸形、持续性低镁血症和双角子宫,肾脏结构正常。在基因分析之后,两名患者根据确定的变异进行了治疗调整。结论:本研究强调了MODY在儿科人群中的临床和遗传异质性,并强调了综合NGS面板对准确诊断的价值,即使在不完全符合经典MODY标准的患者中也是如此。新的GCK变异的鉴定和罕见亚型的检测进一步扩大了儿童单基因糖尿病的突变和表型谱。这些发现强调了将特定人群基因组数据纳入临床实践的重要性,以及随着新的分子和功能证据的出现,定期重新评估基因与疾病的关联。最终,将分子诊断整合到常规儿科糖尿病护理将提高诊断率,优化管理,并改善受影响家庭的长期预后。
{"title":"Revealing Monogenic Diabetes: Clinical and Genetic Features of Pediatric MODY Cases in Türkiye: Single Center Experience.","authors":"Aslihan Sanri, Tugba Kontbay Cetin, Emel Gul Acikgoz, Mehmet Burak Mutlu, Ozlem Sezer","doi":"10.1155/pedi/4035026","DOIUrl":"10.1155/pedi/4035026","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Objective: &lt;/strong&gt;Maturity-onset diabetes of the young (MODY) represents a genetically and clinically heterogeneous form of monogenic diabetes caused by defects in pancreatic β-cell function. Accurate molecular diagnosis is essential for distinguishing MODY from type 1 and type 2 diabetes, enabling precision-based management and targeted therapy. This study aimed to evaluate the genetic and clinical features of pediatric patients with MODY, to assess the prevalence of common and rare subtypes, and to report novel pathogenic variants identified in a Turkish cohort.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;This single-center, retrospective cohort study evaluated 81 pediatric patients with suspected MODY followed between 2022 and 2025. Genetic analysis was performed using targeted next-generation sequencing (NGS) panels, including &lt;i&gt;HNF4A&lt;/i&gt;, &lt;i&gt;GCK&lt;/i&gt;, &lt;i&gt;HNF1A&lt;/i&gt;, &lt;i&gt;PDX1&lt;/i&gt;, &lt;i&gt;HNF1B&lt;/i&gt;, &lt;i&gt;NEUROD1&lt;/i&gt;, &lt;i&gt;INS&lt;/i&gt;, &lt;i&gt;ABCC8&lt;/i&gt;, &lt;i&gt;KCNJ11&lt;/i&gt;, &lt;i&gt;APPL1&lt;/i&gt;, and &lt;i&gt;CEL&lt;/i&gt;. Patients were selected based on the presence of at least two clinical features suggestive of MODY, as defined by the 2022 International Society for Pediatric and Adolescent Diabetes (ISPAD) Clinical Practice Consensus Guidelines. Demographic, biochemical, and clinical data were extracted from hospital records and analyzed descriptively.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;Genetic variants were identified in 25 of 81 patients (30.9%), including pathogenic, likely pathogenic, and variants of uncertain significance (VUS). Of these, 22 variants were classified as pathogenic or likely pathogenic, corresponding to a diagnostic yield of 27.2%. The most frequently affected gene was &lt;i&gt;GCK&lt;/i&gt; (72.0%), followed by &lt;i&gt;HNF1A&lt;/i&gt; (8.0%), with single cases identified in &lt;i&gt;HNF1B&lt;/i&gt;, &lt;i&gt;INS&lt;/i&gt;, &lt;i&gt;PDX1&lt;/i&gt;, &lt;i&gt;CEL&lt;/i&gt;, &lt;i&gt;and KCNJ11&lt;/i&gt;. Rare MODY subtypes collectively accounted for 20.0%. Three novel &lt;i&gt;GCK&lt;/i&gt; variants c.1055T &gt;C, c.1229A &gt;C, and c.185_186insA were identified. One patient with syndromic features harbored a heterozygous 17q12 microdeletion encompassing &lt;i&gt;HNF1B&lt;/i&gt;, approximately 1.5 Mb in size, and presented with global developmental delay, intellectual disability, epilepsy, dysmorphic facial features, persistent hypomagnesemia, and a bicornuate uterus with normal renal structure. Following genetic analysis, two patients had therapy adjustments based on the identified variants.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusion: &lt;/strong&gt;This study underscores the clinical and genetic heterogeneity of MODY in the pediatric population and reinforces the value of comprehensive NGS panels for accurate diagnosis, even in patients who do not fully meet classical MODY criteria. The identification of novel &lt;i&gt;GCK&lt;/i&gt; variants and the detection of rare subtypes further expand the mutational and phenotypic spectrum of pediatric monogenic diabetes. These findings highlight the importance of incorporating population-specific genomic data into clinical practice and of periodically re-evaluating gene-di","PeriodicalId":19797,"journal":{"name":"Pediatric Diabetes","volume":"2025 ","pages":"4035026"},"PeriodicalIF":5.6,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12685419/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145715231","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Global Prevalence of Microvascular Complications in Children and Adolescents With Type 1 and Type 2 Diabetes: A Systematic Review and Meta-Analysis. 1型和2型糖尿病儿童和青少年微血管并发症的全球患病率:一项系统综述和荟萃分析
IF 5.6 3区 医学 Q2 ENDOCRINOLOGY & METABOLISM Pub Date : 2025-11-26 eCollection Date: 2025-01-01 DOI: 10.1155/pedi/8398194
Yasmin Ezzatvar, Ignacio Hormazábal-Aguayo, Jacinto Muñoz-Pardeza, Jacqueline Páez-Herrera, Rodrigo Yáñez-Sepúlveda, Antonio García-Hermoso

Aim: To quantify the prevalence of microvascular complications of children and adolescents with type 1 and type 2 diabetes by performing a meta-analysis of observational studies.

Methods: A systematic search in PubMed, EMBASE, and Web of Science was performed from 2000 to August 2025. Studies that reported the prevalence of microvascular complications in children and adolescents with diabetes were included. Study characteristics and prevalence estimates were extracted from each study. Pooled prevalence rates for microvascular complications were calculated using a random-effects model with Freeman-Tukey double arcsine transformation to stabilize variance.

Results: A total of 57 studies were included, comprising 51,819 children and adolescents diagnosed with diabetes (type 1: n = 44,150 and type 2: n = 7,669), with a mean age of 14.5 and 15.2 years old, respectively. Pooled prevalence of complications in youth with type 1 vs. type 2 diabetes was 22.07% (95% CI: 16.86-27.75) vs. 11.04% (95% CI: 2.73-23.45) for peripheral neuropathy, 31.98% (95% CI: 11.13-57.44) vs. 15.37% (95% CI: 3.09-34.29) for autonomic neuropathy, 13.76% (95% CI: 6.43-23.24) vs. 2.97% (95% CI: 0.00-10.33) for retinopathy, and 13.70% (95% CI: 10.25-17.54) vs. 12.63% (95% CI: 7.99-18.07) for nephropathy, with high heterogeneity across studies and no significant differences between diabetes types. Meta-regression analyses showed no significant associations between complication prevalence and HbA1c, diabetes duration, lipid levels, cohort year, or age.

Conclusions/interpretation: Microvascular complications affect at least one in 10 youths with diabetes before age 20, with similar prevalence in type 1 and type 2 diabetes. Given the high rates and early onset, routine screening and early intervention are essential for all young people with diabetes to prevent or limit progression of vascular damage, regardless of diabetes type, glycemic stability, or disease duration.

目的:通过对观察性研究进行荟萃分析,量化1型和2型糖尿病儿童和青少年微血管并发症的患病率。方法:从2000年至2025年8月系统检索PubMed、EMBASE和Web of Science。研究报告了儿童和青少年糖尿病患者微血管并发症的患病率。从每项研究中提取研究特征和患病率估计。利用Freeman-Tukey双反正弦变换的随机效应模型计算微血管并发症的合并患病率以稳定方差。结果:共纳入57项研究,包括51,819名诊断为糖尿病的儿童和青少年(1型:n = 44150, 2型:n = 7669),平均年龄分别为14.5岁和15.2岁。青少年1型糖尿病和2型糖尿病并发症的总患病率分别为:周围神经病变22.07% (95% CI: 16.86-27.75)和11.04% (95% CI: 2.73-23.45),自主神经病变31.98% (95% CI: 11.13-57.44)和15.37% (95% CI: 3.09-34.29),视网膜病变13.76% (95% CI: 6.43-23.24)和2.97% (95% CI: 0.00-10.33), 13.70% (95% CI: 10.25-17.54)和12.63% (95% CI: 12.63%)。7.99-18.07),研究间具有高度异质性,糖尿病类型间无显著差异。荟萃回归分析显示,并发症患病率与HbA1c、糖尿病病程、血脂水平、队列年份或年龄之间无显著关联。结论/解释:微血管并发症影响至少十分之一的20岁前青少年糖尿病患者,1型和2型糖尿病患病率相似。鉴于高发病率和早发性,常规筛查和早期干预对于所有年轻糖尿病患者预防或限制血管损伤进展至关重要,无论糖尿病类型、血糖稳定性或疾病持续时间如何。
{"title":"Global Prevalence of Microvascular Complications in Children and Adolescents With Type 1 and Type 2 Diabetes: A Systematic Review and Meta-Analysis.","authors":"Yasmin Ezzatvar, Ignacio Hormazábal-Aguayo, Jacinto Muñoz-Pardeza, Jacqueline Páez-Herrera, Rodrigo Yáñez-Sepúlveda, Antonio García-Hermoso","doi":"10.1155/pedi/8398194","DOIUrl":"10.1155/pedi/8398194","url":null,"abstract":"<p><strong>Aim: </strong>To quantify the prevalence of microvascular complications of children and adolescents with type 1 and type 2 diabetes by performing a meta-analysis of observational studies.</p><p><strong>Methods: </strong>A systematic search in PubMed, EMBASE, and Web of Science was performed from 2000 to August 2025. Studies that reported the prevalence of microvascular complications in children and adolescents with diabetes were included. Study characteristics and prevalence estimates were extracted from each study. Pooled prevalence rates for microvascular complications were calculated using a random-effects model with Freeman-Tukey double arcsine transformation to stabilize variance.</p><p><strong>Results: </strong>A total of 57 studies were included, comprising 51,819 children and adolescents diagnosed with diabetes (type 1: <i>n</i> = 44,150 and type 2: <i>n</i> = 7,669), with a mean age of 14.5 and 15.2 years old, respectively. Pooled prevalence of complications in youth with type 1 vs. type 2 diabetes was 22.07% (95% CI: 16.86-27.75) vs. 11.04% (95% CI: 2.73-23.45) for peripheral neuropathy, 31.98% (95% CI: 11.13-57.44) vs. 15.37% (95% CI: 3.09-34.29) for autonomic neuropathy, 13.76% (95% CI: 6.43-23.24) vs. 2.97% (95% CI: 0.00-10.33) for retinopathy, and 13.70% (95% CI: 10.25-17.54) vs. 12.63% (95% CI: 7.99-18.07) for nephropathy, with high heterogeneity across studies and no significant differences between diabetes types. Meta-regression analyses showed no significant associations between complication prevalence and HbA1c, diabetes duration, lipid levels, cohort year, or age.</p><p><strong>Conclusions/interpretation: </strong>Microvascular complications affect at least one in 10 youths with diabetes before age 20, with similar prevalence in type 1 and type 2 diabetes. Given the high rates and early onset, routine screening and early intervention are essential for all young people with diabetes to prevent or limit progression of vascular damage, regardless of diabetes type, glycemic stability, or disease duration.</p>","PeriodicalId":19797,"journal":{"name":"Pediatric Diabetes","volume":"2025 ","pages":"8398194"},"PeriodicalIF":5.6,"publicationDate":"2025-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12674870/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145678375","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparative Effectiveness of Switching From First-Generation Basal Insulins to Either Glargine 300 U/mL or Degludec 100 U/mL in Children and Adolescents With Type 1 Diabetes: Results From the ISPED CARD Clinical Registry. 儿童和青少年1型糖尿病患者从第一代基础胰岛素切换到甘精300 U/mL或Degludec 100 U/mL的比较有效性:来自ISPED CARD临床登记的结果
IF 5.6 3区 医学 Q2 ENDOCRINOLOGY & METABOLISM Pub Date : 2025-11-21 eCollection Date: 2025-01-01 DOI: 10.1155/pedi/5514402
Ivana Rabbone, Riccardo Bonfanti, Giusi Graziano, Fortunato Lombardo, Antonio Nicolucci, Marco Marigliano, Maria Chiara Rossi, Giacomo Vespasiani, Valentino Cherubini

Background: To assess the real-world effectiveness of switching from first-generation basal insulins (1BIs) to either glargine U300 (Gla-300) or degludec U100 (Deg-100) in children and adolescents with type 1 diabetes (T1D), using data from the Italian ISPED CARD clinical registry.

Materials and methods: This multicenter retrospective observational study included 1063 pediatric patients with T1D from 22 diabetes centers across Italy who switched from 1BI to either Gla-300 (64.6%) or Deg-100 (35.4%) between 2021 and 2023. Propensity score matching (PSM) was applied to create comparable groups (n = 353 per group). Primary endpoint was the change in HbA1c at 6 months. Secondary endpoints included fasting blood glucose (FBG), standardized body mass index (BMI/SDS), and insulin doses at 6 and 12 months. Longitudinal models for repeated measures were used to assess treatment effectiveness.

Results: Both groups showed significant and clinically relevant reductions in HbA1c at 6 months from ~ 8.7% to ~ 7.4% (-1.3 percentage points), maintained at 12 months, with no significant differences between groups. FBG also decreased significantly in both groups, slightly favoring Deg-100, but without statistical significance between groups. BMI/SDS remained stable. Gla-300 was associated with a slight increase in basal insulin dose over 12 months, while Deg-100 showed a temporary reduction at 6 months. A significant reduction in short-acting insulin dose (-0.03 U/kg) was observed in both groups.

Conclusion: Switching from 1BI to either Gla-300 or Deg-100 significantly improves glycemic control in pediatric T1D patients without weight gain. Although both insulins showed comparable effectiveness, differences in titration patterns highlight the need for individualized treatment strategies and improved clinician education in insulin optimization. Safety outcomes, particularly hypoglycemia, could not be assessed.

背景:利用意大利ISPED CARD临床登记的数据,评估儿童和青少年1型糖尿病(T1D)患者从第一代基础胰岛素(1BIs)切换到甘精U300 (Gla-300)或degludec U100 (Deg-100)的实际有效性。材料和方法:这项多中心回顾性观察性研究包括来自意大利22个糖尿病中心的1063名T1D儿童患者,他们在2021年至2023年间从1BI切换到Gla-300(64.6%)或Deg-100(35.4%)。采用倾向评分匹配(PSM)创建可比较组(每组n = 353)。主要终点是6个月时HbA1c的变化。次要终点包括6个月和12个月时的空腹血糖(FBG)、标准化体重指数(BMI/SDS)和胰岛素剂量。采用重复测量的纵向模型来评估治疗效果。结果:两组HbA1c在6个月时从~ 8.7%降至~ 7.4%(-1.3个百分点),并维持在12个月,两组间无显著差异。两组FBG均显著降低,稍偏向于℃-100,但组间无统计学意义。BMI/SDS保持稳定。Gla-300在12个月内与基础胰岛素剂量轻微增加有关,而Deg-100在6个月时显示暂时减少。两组患者短效胰岛素剂量均显著降低(-0.03 U/kg)。结论:从1BI切换到Gla-300或Deg-100可显著改善儿童T1D患者的血糖控制,且体重未增加。尽管两种胰岛素都显示出相当的疗效,但滴定模式的差异突出了个性化治疗策略和提高胰岛素优化临床医生教育的必要性。安全性结果,特别是低血糖,无法评估。
{"title":"Comparative Effectiveness of Switching From First-Generation Basal Insulins to Either Glargine 300 U/mL or Degludec 100 U/mL in Children and Adolescents With Type 1 Diabetes: Results From the ISPED CARD Clinical Registry.","authors":"Ivana Rabbone, Riccardo Bonfanti, Giusi Graziano, Fortunato Lombardo, Antonio Nicolucci, Marco Marigliano, Maria Chiara Rossi, Giacomo Vespasiani, Valentino Cherubini","doi":"10.1155/pedi/5514402","DOIUrl":"10.1155/pedi/5514402","url":null,"abstract":"<p><strong>Background: </strong>To assess the real-world effectiveness of switching from first-generation basal insulins (1BIs) to either glargine U300 (Gla-300) or degludec U100 (Deg-100) in children and adolescents with type 1 diabetes (T1D), using data from the Italian ISPED CARD clinical registry.</p><p><strong>Materials and methods: </strong>This multicenter retrospective observational study included 1063 pediatric patients with T1D from 22 diabetes centers across Italy who switched from 1BI to either Gla-300 (64.6%) or Deg-100 (35.4%) between 2021 and 2023. Propensity score matching (PSM) was applied to create comparable groups (<i>n</i> = 353 per group). Primary endpoint was the change in HbA1c at 6 months. Secondary endpoints included fasting blood glucose (FBG), standardized body mass index (BMI/SDS), and insulin doses at 6 and 12 months. Longitudinal models for repeated measures were used to assess treatment effectiveness.</p><p><strong>Results: </strong>Both groups showed significant and clinically relevant reductions in HbA1c at 6 months from ~ 8.7% to ~ 7.4% (-1.3 percentage points), maintained at 12 months, with no significant differences between groups. FBG also decreased significantly in both groups, slightly favoring Deg-100, but without statistical significance between groups. BMI/SDS remained stable. Gla-300 was associated with a slight increase in basal insulin dose over 12 months, while Deg-100 showed a temporary reduction at 6 months. A significant reduction in short-acting insulin dose (-0.03 U/kg) was observed in both groups.</p><p><strong>Conclusion: </strong>Switching from 1BI to either Gla-300 or Deg-100 significantly improves glycemic control in pediatric T1D patients without weight gain. Although both insulins showed comparable effectiveness, differences in titration patterns highlight the need for individualized treatment strategies and improved clinician education in insulin optimization. Safety outcomes, particularly hypoglycemia, could not be assessed.</p>","PeriodicalId":19797,"journal":{"name":"Pediatric Diabetes","volume":"2025 ","pages":"5514402"},"PeriodicalIF":5.6,"publicationDate":"2025-11-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12662695/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145649127","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Acidosis at Diagnosis of Type 1 Diabetes Mellitus: Relation With Kidney Function. 1型糖尿病的酸中毒诊断与肾功能的关系。
IF 5.6 3区 医学 Q2 ENDOCRINOLOGY & METABOLISM Pub Date : 2025-11-17 eCollection Date: 2025-01-01 DOI: 10.1155/pedi/3188571
Stefano Guarino, Dario Iafusco, Anna Di Sessa, Paola Tirelli, Giulio Rivetti, Giorgia Ippolito, Mario Bartiromo, Grazia Cirillo, Angela Zanfardino, Emanuele Miraglia Del Giudice, Pierluigi Marzuillo

Aims: Acidosis at type 1 diabetes mellitus (T1DM) onset results from unregulated massive overproduction of ketoacids. However, renal tubular damage (RTD), a complication of T1DM onset, may impair bicarbonate reabsorption, exacerbating acidosis. We aimed to assess RTD role in acidosis at T1DM onset.

Methods: RTD was defined by urinary β2-microglobulin > 0.33 mg/L and/or neutrophil gelatinase-associated lipocalin (NGAL) > 95th percentile for age. Acute kidney injury (AKI) was classified using Kidney Disease/Improving Global Outcomes (KDIGO) criteria. Participants were grouped by serum ketone levels (cut-off: 3 mmol/L, above which indicates diabetic ketoacidosis [DKA]) and bicarbonate levels (cut-off: 22 mmol/L, below which indicates acidosis):- Group 1: Ketones ≥ 3 mmol/L, bicarbonate < 22 mmol/L.- Group 2: Ketones < 3 mmol/L, bicarbonate < 22 mmol/L.- Group 3: Ketones ≥ 3 mmol/L, bicarbonate ≥ 22 mmol/L.- Group 4: Ketones < 3 mmol/L, bicarbonate ≥ 22 mmol/L.

Results: Of 185 individuals, 111 (60%) were in Group 1, 18 (9.7%) in Group 2, 8 (4.3%) in Group 3, and 48 (26%) in Group 4. Group 1 had the most severe clinical and biochemical derangements, followed by Groups 2, 3, and 4. Logistic regression, adjusted for AKI, relative difference of weight loss and glycated hemoglobin (HbA1c), identified RTD (odds ratio [OR] = 22.3; 95% confidence interval [CI]: 6.9-71.5; p  < 0.001), and relative difference of weight loss, (OR = 1.2; 95% CI: 1.1-1.4; p  < 0.006), as significant factors associated with Group 1 and only RTD (OR = 29.9; 95% CI: 3.0-292.9; p=0.004) as significant factor associated with Group 2. Serum bicarbonate and blood pH showed an inverse correlation with urinary NGAL (r 2 = 0.61 and 0.56, respectively, both p  < 0.001) and β2-microglobulin (r 2 = 0.67 and 0.59, respectively, both p  < 0.001), regardless of ketone levels. The ketone-to-bicarbonate ratio predicted RTD (area under the receiver-operating characteristic (ROC) curve (AUROC) = 0.94; 95% CI: 0.91-0.97; p  < 0.001), while serum bicarbonate levels predicted normal renal tubular function (AUROC = 0.95; 95% CI: 0.92-0.98; p  < 0.001).

Conclusions: A link exists between biological markers of RTD and metabolic acidosis at T1DM onset.

目的:1型糖尿病(T1DM)发病时的酸中毒是由于不受控制的大量过量产生酮酸。然而,肾小管损伤(RTD), T1DM发病的并发症,可能损害碳酸氢盐的重吸收,加剧酸中毒。我们的目的是评估RTD在T1DM发病时酸中毒中的作用。方法:以尿β2微球蛋白> 0.33 mg/L和/或中性粒细胞明胶酶相关脂钙蛋白(NGAL) >为年龄第95百分位定义RTD。急性肾损伤(AKI)采用肾脏疾病/改善全球预后(KDIGO)标准进行分类。参与者按血清酮水平(临界值:3 mmol/L,高于临界值表明糖尿病酮症酸中毒[DKA])和碳酸氢盐水平(临界值:22 mmol/L,低于临界值表明酸中毒)分组:- 1组:酮≥3 mmol/L,碳酸氢盐结果:185个人中,1组111人(60%),2组18人(9.7%),3组8人(4.3%),4组48人(26%)。第1组临床及生化紊乱最严重,第2、3、4组次之。经AKI校正后的Logistic回归、体重减轻和糖化血红蛋白(HbA1c)的相对差异发现,RTD(优势比[OR] = 22.3; 95%可信区间[CI]: 6.9-71.5; p < 0.001)和体重减轻的相对差异(OR = 1.2; 95% CI: 1.1-1.4; p < 0.006)是与组1相关的显著因素,只有RTD (OR = 29.9; 95% CI: 3.0-292.9; p=0.004)是与组2相关的显著因素。血清碳酸氢盐和血pH值与尿NGAL (r 2分别= 0.61和0.56,p < 0.001)和β2微球蛋白(r 2分别= 0.67和0.59,p < 0.001)呈负相关,与酮水平无关。酮与碳酸氢盐比值预测RTD(受试者工作特征曲线下面积(AUROC)) = 0.94;95% ci: 0.91-0.97;p < 0.001),而血清碳酸氢盐水平预测肾小管功能正常(AUROC = 0.95; 95% CI: 0.92-0.98; p < 0.001)。结论:T1DM发病时,RTD的生物学标志物与代谢性酸中毒之间存在联系。
{"title":"Acidosis at Diagnosis of Type 1 Diabetes Mellitus: Relation With Kidney Function.","authors":"Stefano Guarino, Dario Iafusco, Anna Di Sessa, Paola Tirelli, Giulio Rivetti, Giorgia Ippolito, Mario Bartiromo, Grazia Cirillo, Angela Zanfardino, Emanuele Miraglia Del Giudice, Pierluigi Marzuillo","doi":"10.1155/pedi/3188571","DOIUrl":"10.1155/pedi/3188571","url":null,"abstract":"<p><strong>Aims: </strong>Acidosis at type 1 diabetes mellitus (T1DM) onset results from unregulated massive overproduction of ketoacids. However, renal tubular damage (RTD), a complication of T1DM onset, may impair bicarbonate reabsorption, exacerbating acidosis. We aimed to assess RTD role in acidosis at T1DM onset.</p><p><strong>Methods: </strong>RTD was defined by urinary β2-microglobulin > 0.33 mg/L and/or neutrophil gelatinase-associated lipocalin (NGAL) > 95<sup>th</sup> percentile for age. Acute kidney injury (AKI) was classified using Kidney Disease/Improving Global Outcomes (KDIGO) criteria. Participants were grouped by serum ketone levels (cut-off: 3 mmol/L, above which indicates diabetic ketoacidosis [DKA]) and bicarbonate levels (cut-off: 22 mmol/L, below which indicates acidosis):- Group 1: Ketones ≥ 3 mmol/L, bicarbonate < 22 mmol/L.- Group 2: Ketones < 3 mmol/L, bicarbonate < 22 mmol/L.- Group 3: Ketones ≥ 3 mmol/L, bicarbonate ≥ 22 mmol/L.- Group 4: Ketones < 3 mmol/L, bicarbonate ≥ 22 mmol/L.</p><p><strong>Results: </strong>Of 185 individuals, 111 (60%) were in Group 1, 18 (9.7%) in Group 2, 8 (4.3%) in Group 3, and 48 (26%) in Group 4. Group 1 had the most severe clinical and biochemical derangements, followed by Groups 2, 3, and 4. Logistic regression, adjusted for AKI, relative difference of weight loss and glycated hemoglobin (HbA1c), identified RTD (odds ratio [OR] = 22.3; 95% confidence interval [CI]: 6.9-71.5; <i>p</i>  < 0.001), and relative difference of weight loss, (OR = 1.2; 95% CI: 1.1-1.4; <i>p</i>  < 0.006), as significant factors associated with Group 1 and only RTD (OR = 29.9; 95% CI: 3.0-292.9; <i>p</i>=0.004) as significant factor associated with Group 2. Serum bicarbonate and blood pH showed an inverse correlation with urinary NGAL (<i>r</i> <sup>2</sup> = 0.61 and 0.56, respectively, both <i>p</i>  < 0.001) and β2-microglobulin (<i>r</i> <sup>2</sup> = 0.67 and 0.59, respectively, both <i>p</i>  < 0.001), regardless of ketone levels. The ketone-to-bicarbonate ratio predicted RTD (area under the receiver-operating characteristic (ROC) curve (AUROC) = 0.94; 95% CI: 0.91-0.97; <i>p</i>  < 0.001), while serum bicarbonate levels predicted normal renal tubular function (AUROC = 0.95; 95% CI: 0.92-0.98; <i>p</i>  < 0.001).</p><p><strong>Conclusions: </strong>A link exists between biological markers of RTD and metabolic acidosis at T1DM onset.</p>","PeriodicalId":19797,"journal":{"name":"Pediatric Diabetes","volume":"2025 ","pages":"3188571"},"PeriodicalIF":5.6,"publicationDate":"2025-11-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12643667/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145605059","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Pediatric Diabetes
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1